{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:00:33Z","timestamp":1791172833338,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-025-00689-3","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:42:52Z","timestamp":1744080172000},"page":"383-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tapinarof Cream 1%: Pediatric First Approval"],"prefix":"10.1007","volume":"27","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"5","key":"689_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","volume":"23","author":"E Kleinman","year":"2022","unstructured":"Kleinman E, Laborada J, Metterle L, et al. What\u2019s new in topicals for atopic dermatitis? Am J Clin Dermatol. 2022;23(5):595\u2013603.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"689_CR2","doi-asserted-by":"publisher","first-page":"2300354","DOI":"10.1080\/09546634.2023.2300354","volume":"35","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Silverberg JI, Hebert AA, et al. Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis. J Dermatolog Treat. 2024;35(1):2300354.","journal-title":"J Dermatolog Treat"},{"key":"689_CR3","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases. Atopic dermatitis. 2022. https:\/\/www.niams.nih.gov\/health-topics\/atopic-dermatitis. Accessed 28 Jan 2025."},{"issue":"10","key":"689_CR4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110\u20139.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"689_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: se ction 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"689_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jaci.2023.01.010","volume":"151","author":"S Butala","year":"2023","unstructured":"Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"689_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.36849\/JDD.8026","volume":"23","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Silverberg JI, Hebert AA, et al. Targeting the aryl hydrocarbon receptor to address the challenges of atopic dermatitis. J Drugs Dermatol. 2024;23(2):23\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"689_CR8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","volume":"84","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059\u201367.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"689_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/exd.14541","volume":"31","author":"J Hwang","year":"2022","unstructured":"Hwang J, Newton EM, Hsiao J, et al. Aryl hydrocarbon receptor\/nuclear factor E2-related factor 2 (AHR\/NRF2) signalling: a novel therapeutic target for atopic dermatitis. Exp Dermatol. 2022;31(4):485\u201397.","journal-title":"Exp Dermatol"},{"key":"689_CR10","unstructured":"Organon. FDA approves VTAMA\u00ae (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older [media release]. 16 Dec 2024. https:\/\/www.organon.com\/."},{"key":"689_CR11","unstructured":"Dermavant Sciences, Inc. VTAMA\u00ae (tapinarof) cream, for topical use: US prescribing information. 2024. https:\/\/www.fda.gov\/drugs. Accessed 21 Jan 2025."},{"key":"689_CR12","unstructured":"Dermavant Sciences. FDA approves Dermavant\u2019s VTAMA\u00ae (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25 years. 2022. https:\/\/dermavant.com\/. Accessed 22 Jan 2025."},{"issue":"11","key":"689_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Tapinarof cream 1%: first approval. Drugs. 2022;82(11):1221\u20138.","journal-title":"Drugs"},{"issue":"9","key":"689_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40267-023-01014-z","volume":"39","author":"M Shirley","year":"2023","unstructured":"Shirley M. Tapinarof cream 1% in plaque psoriasis: a profile of its use. Drugs Therapy Perspect. 2023;39(9):303\u20138.","journal-title":"Drugs Therapy Perspect."},{"key":"689_CR15","unstructured":"Dermavant Sciences. Dermavant announces approval of tapinarof in both psoriasis and atopic dermatitis in Japan [media release]. 25 Jun 2024. http:\/\/www.dermavant.com."},{"issue":"6","key":"689_CR16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jdv.18925","volume":"37","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Saint-Cyr Proulx E, Jack C, et al. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research. J Eur Acad Dermatol Venereol. 2023;37(6):1168\u201374.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"689_CR17","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.jaad.2021.04.103","volume":"85","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Rubenstein DS, Peist K, et al. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. J Am Acad Dermatol. 2021;85(3):e201\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"689_CR18","unstructured":"Welichem Biotech Inc. Welichem and Stiefel, a GSK company, complete the acquisition by Stiefel of the novel anti-inflammatory agent, WBI-1001 [media release]. 31 Jul 2012. http:\/\/www.welichem.com."},{"key":"689_CR19","unstructured":"Stiefel, Welichem Biotech Inc. Stiefel, a GSK company, enters into an agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis [media release]. 30 May 2012. http:\/\/www.stiefel.com."},{"key":"689_CR20","unstructured":"Dermavant Sciences. Dermavant Sciences announces closing of transaction with GSK for purchase of rights to tapinarof [media release]. 21 Aug 2018. http:\/\/www.dermavant.com."},{"key":"689_CR21","unstructured":"Dermavant Sciences. Dermavant enters into exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 15 Jan 2020. http:\/\/www.dermavant.com."},{"key":"689_CR22","unstructured":"Torii Pharmaceutical Co., Ltd. Torii signs exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 15 Jan 2020. https:\/\/www.torii.co.jp\/en\/."},{"key":"689_CR23","unstructured":"Organon. Organon completes acquisition of Dermavant, including innovative dermatologic therapy, VTAMA\u00ae (tapinarof) cream, 1% [media release]. 28 Oct 2024. http:\/\/www.organon.com."},{"key":"689_CR24","unstructured":"Dermavant Sciences. Dermavant Sciences announces appointment of Cyril Allouche as Chief Financial Officer and provides recent corporate update [media release]. 27 Mar 2019. http:\/\/www.dermavant.com."},{"key":"689_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00929-9","author":"ASM Paller","year":"2025","unstructured":"Paller ASM, Hebert AA, Gonzalez ME, et al. Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00929-9.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"689_CR26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/1346-8138.17451","volume":"51","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, et al. Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol. 2024;51(11):1404\u201313.","journal-title":"J Dermatol"},{"issue":"3","key":"689_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"92","key":"689_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44\u20137.","journal-title":"Acta Derm Venereol"},{"key":"689_CR29","unstructured":"Dermavant Sciences. Dermavant presents ADORING 3 LTE final data on complete skin clearance and treatment-free interval for VTAMA\u00ae (tapinarof) cream, 1% in adults and children as young as two years old with atopic dermatitis at 2024 Fall Clinical Dermatology Conference [media release]. 24 Oct 2024. http:\/\/www.dermavant.com."},{"issue":"6","key":"689_CR30","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.460","volume":"8","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis [abstract]. SKIN J Cutaneous Med. 2024;8(6): s460.","journal-title":"SKIN J Cutaneous Med"},{"issue":"1","key":"689_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89-98.e3.","journal-title":"J Am Acad Dermatol"},{"key":"689_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17587","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Murata R, et al. A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol. 2024. https:\/\/doi.org\/10.1111\/1346-8138.17587.","journal-title":"J Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00689-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00689-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:27:49Z","timestamp":1745580469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00689-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00689-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"29 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}